Sun 6/16/2019 06:38 ET
DJIA26089.6118.260.07%TELCO173.111.160.67%GOLD1345.351.610.12%Shanghai2881.9728.530.99%
S&P 5002886.984.620.16%BANKS435.691.740.40%OIL52.520.240.46%BITCOIN8635.9257.860.67%
NASDAQ7796.6640.540.52%PHARM570.671.260.22%US/EU1.120.000.01%Futures2891.622.890.10%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Wall Street Pit    Stock Due Diligence for All

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search
  
From: SunTzu772 (Rep: 1129)Date: 06/12/2019 10:04
Forum: Wall Street Pit - Msg #2789832Thread #674085832 (Rec: 6)
Xynomic Completes Pre-IND Meeting with US FDA for XP-102, a Novel Pan-RAF Inhibitor against Colorectal Cancer and Lung Cancer

June 12, 2019 10:00 ET | Source: Xynomic Pharmaceuticals Holdings, Inc.


RALEIGH, N.C. and SHANGHAI, June 12, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that it recently held a pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its pan-PAF inhibitor XP-102 (BI 882370) for the treatment of cancers. The FDA addressed Xynomic' questions related to CMC, nonclinical and clinical protocol, and provided valuable advice on overall clinical development plan to advance this drug candidate. Xynomic is on track to file this Investigational New Drug (“IND”) application in the second half of 2019.
XP-102 is a second generation potent and selective pan-RAF inhibitor uniquely binding to the DFG-out conformation, whereas marketed BRAF inhibitors occupy the DFG-in conformation. In the colorectal cancer (CRC) animal models, XP-102 showed superior anti-tumor activity to vemurafenib, a marketed BRAF inhibitor in both the Colo-205V600V/E model and HT-29V600V/E model. XP-102 in combination with cetuximab induced tumor regressions in the less sensitive HT-29 model.

"Our meeting with the FDA was a major step forward and the feedbacks provided by the agency was valuable in our development of clinical and regulatory strategies that will support our goal of advancing XP-102 through clinical development," said Y. Mark Xu, Xynomic' Chairman and CEO. "We believe that XP-102 holds potential as an innovative therapy against B-RAF V600 mutated solid tumors including CRC and non-small cell lung cancer and hairy cell leukemia."

http://www.globenewswire.com/news-release/2019/06/12/1867687/0/en/Xynomic-Completes-Pre-IND-Meeting-with-US-FDA-for-XP-102-a-Novel-Pan-RAF-Inhibitor-against-Colorectal-Cancer-and-Lung-Cancer.html



------------------- "Opportunities multiply as they are seized" -- Sun Tzu circa 500 B.C. -------------------

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser SunTzu772: Reward | Watch | Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.